|
1
|
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.
|
Nat Genet
|
2010
|
17.89
|
|
2
|
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
|
N Engl J Med
|
2005
|
15.18
|
|
3
|
Meta-analysis and imputation refines the association of 15q25 with smoking quantity.
|
Nat Genet
|
2010
|
8.55
|
|
4
|
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
|
JAMA
|
2011
|
8.24
|
|
5
|
LDL-cholesterol concentrations: a genome-wide association study.
|
Lancet
|
2008
|
6.44
|
|
6
|
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
|
Lancet
|
2006
|
5.67
|
|
7
|
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
|
N Engl J Med
|
2010
|
4.42
|
|
8
|
Genetic variants influencing circulating lipid levels and risk of coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2010
|
4.08
|
|
9
|
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
|
Diabetes Care
|
2006
|
3.37
|
|
10
|
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.
|
PLoS Genet
|
2012
|
3.21
|
|
11
|
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.
|
Circulation
|
2007
|
3.01
|
|
12
|
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
|
J Am Coll Cardiol
|
2011
|
2.55
|
|
13
|
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
|
Circulation
|
2008
|
2.30
|
|
14
|
National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.
|
Heart Lung Circ
|
2005
|
2.16
|
|
15
|
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
|
J Am Coll Cardiol
|
2006
|
2.15
|
|
16
|
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
|
Eur Heart J
|
2014
|
1.88
|
|
17
|
A genome-wide association search for type 2 diabetes genes in African Americans.
|
PLoS One
|
2012
|
1.72
|
|
18
|
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
|
Eur Heart J
|
2004
|
1.46
|
|
19
|
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study.
|
Atherosclerosis
|
2007
|
1.36
|
|
20
|
Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.
|
Circulation
|
2013
|
1.23
|
|
21
|
Residual macrovascular risk in 2013: what have we learned?
|
Cardiovasc Diabetol
|
2014
|
1.20
|
|
22
|
The emerging role of HDL in glucose metabolism.
|
Nat Rev Endocrinol
|
2012
|
1.17
|
|
23
|
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
|
Arch Intern Med
|
2009
|
1.06
|
|
24
|
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
|
Am Heart J
|
2009
|
1.04
|
|
25
|
Retracted
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
|
J Am Coll Cardiol
|
2011
|
0.99
|
|
26
|
Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't know.
|
Diabetes Res Clin Pract
|
2011
|
0.95
|
|
27
|
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
|
Am J Cardiol
|
2003
|
0.92
|
|
28
|
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
|
J Am Coll Cardiol
|
2008
|
0.89
|
|
29
|
The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance.
|
Nucl Recept
|
2007
|
0.88
|
|
30
|
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
|
J Lipid Res
|
2012
|
0.88
|
|
31
|
Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review.
|
Eur J Cardiovasc Prev Rehabil
|
2009
|
0.87
|
|
32
|
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
|
Circ Cardiovasc Genet
|
2011
|
0.84
|
|
33
|
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
|
Atheroscler Suppl
|
2004
|
0.81
|
|
34
|
Effects of inflammation on high-density lipoproteins.
|
Arterioscler Thromb Vasc Biol
|
2002
|
0.81
|
|
35
|
Antioxidant effects of statins in the management of cardiometabolic disorders.
|
J Atheroscler Thromb
|
2014
|
0.81
|
|
36
|
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
|
Curr Med Res Opin
|
2011
|
0.79
|
|
37
|
Correction to the FIELD study report.
|
Lancet
|
2006
|
0.78
|
|
38
|
Phenotypic and functional changes in blood monocytes following adherence to endothelium.
|
PLoS One
|
2012
|
0.77
|
|
39
|
Australia's Heart Research Institute: a remarkable institution in the southern hemisphere. Interviewed by Iona MacDonald.
|
Eur Heart J
|
2009
|
0.75
|
|
40
|
Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction: A propensity score matching analysis from the Korea Acute Myocardial Infarction Registry.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
41
|
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary].
|
Clin Investig Arterioscler
|
2013
|
0.75
|
|
42
|
Lipid-lowering--translating evidence into benefits.
|
Atheroscler Suppl
|
2002
|
0.75
|